For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development expenses | 2,111 | 2,226* | 2,585 | |
| Selling, general and administrative expenses | 1,951 | 4,024* | 2,298 | |
| Loss from operations | -4,062 | -6,250* | -4,883 | |
| Realized gain from sales of trading securities | 238 | 502* | 208 | |
| Unrealized loss from trading securities | -43 | -274* | -39 | |
| Interest income | 22 | 167* | 175 | |
| Loss from disposition of property and equipment | -4 | - | - | |
| Total other income | 213 | 395* | 344 | |
| Net loss | -3,849 | -5,855 | -4,539 | |
| Basic EPS | -5.89 | 0.309 | -0.23 | |
| Diluted EPS | -5.89 | 0.309 | -0.23 | |
| Basic Average Shares | 654,000 | -18,977,000 | 20,155,000 | |
| Diluted Average Shares | 654,000 | -18,977,000 | 20,155,000 | |
enVVeno Medical Corp (NVNO)
enVVeno Medical Corp (NVNO)